Purdue Pharma Canada will pay up to $3 million Canadian to Medical Developments International Limited (MDI) for Canadian rights to MDI’s Penthrox methoxyflurane inhaler for the treatment of moderate to severe pain in trauma patients, and BL&H Co has obtained rights to the product in Korea, according to MDI.
MDI also announced that Penthrox has been approved in the UAE. Penthrox is approved in 15 countries including Australia, the UK, Ireland, and France. In 2014, MDI announced that Galen had acquired a license to market the inhaler in the UK and Ireland. Mundipharma has the rights to Penthrox in most of the rest of Europe.
MDI CEO John Sharman commented on the Purdue deal: “This is an exciting deal for MDI and is a critical step towards providing the Canadian healthcare system with another valuable therapeutic option for the treatment of pain. Purdue has market leading expertise in pain management products and will invest in providing the educational resources to healthcare practitioners on the appropriate use, benefits, and safety profile of Penthrox.”
Purdue Pharma Canada President and CEO Craig Landau said, “Subject to regulatory approval by Health Canada, Penthrox will provide Canadian patients and ER Physicians with an important, non-opioid treatment option for medical situations involving acute trauma pain that is moderate to severe in nature. Penthrox nicely complements, and will provide additional diversification to our existing analgesic product portfolio. We look forward to making Penthrox available to health care professionals and the patients who would benefit from its use in appropriate settings.”
Read the MDI press release.
